IP Library › Granted Patent US 11,787,868
Granted Patent B2
US 11,787,868 · App. 17/130,477 · Granted Oct 17, 2023

Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use

Inventors: Harald Duerr (Starnberg, DE); Sebastian Fenn (Achmuehle/Eurasburg, DE); Ulrich Goepfert (Penzberg, DE); Sabine Imhof-Jung (Planegg, DE); Christian Klein (Bonstetten, CH); Laurent Lariviere (Munich, DE); Michael Molhoj (Munich, DE); Joerg Thomas Regula (Munich, DE); Petra Rueger (Penzberg, DE); Wolfgang Schaefer (Mannheim, DE)
C07K16/2881A61P25/28C07K16/18C07K16/468A61K2039/505C07K2317/31C07K2317/51C07K2317/515C07K2317/52C07K2317/522C07K2317/55C07K2317/56C07K2317/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,787,868
App. No.
17/130,477
Granted
Oct 17, 2023
Kind
B2
Abstract

Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.

Claims (10)

1. A bispecific antibody specifically binding to human A-beta protein and human transferrin receptor, comprising:

a first light chain of SEQ ID NO: 01 or that has a sequence identity to SEQ ID NO: 01 of at least 90%;

a first heavy chain of SEQ ID NO: 02 or that has a sequence identity to SEQ ID NO: 02 of at least 90%;

a second light chain of SEQ ID NO: 03 or that has a sequence identity to SEQ ID NO: 03 of at least 90%; and

a second heavy chain of SEQ ID NO: 10 or that has a sequence identity to SEQ ID NO: 10 of at least 90%,

wherein substitutions, insertions, or deletions occur in regions outside hypervariable regions.

2. The bispecific antibody according to claim 1 , wherein the bispecific antibody is monoclonal.

3. A pharmaceutical formulation, comprising the bispecific antibody according to claim 1 and a pharmaceutically acceptable carrier.

4. A method of treating Alzheimer's disease in an individual, comprising the step of administering an effective amount of the bispecific antibody according to claim 1 to said individual in need thereof.

5. A method of inhibiting or slowing down the formation of plaques in the brain of an individual, comprising the step of administering an effective amount of the bispecific antibody according to claim 1 to said individual in need thereof.

Priority Claims (1)
EP 15188064 · Oct 2, 2015 · regional
Continuity (4)
Division 15941655 · Mar 30, 2018
Continuation PCTEP2016073411 · Sep 30, 2016
Related Publication 20210301030A1 · Sep 30, 2021
Related Publication 20220144963A9 · May 12, 2022
Cited By (2)
US 12,358,997 US 12,735,497